Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


anticoagulants, anticoagulation, apixaban, atrial fibrillation, dabigatran, direct oral anticoagulants, DOACs, edoxaban, new oral anticoagulants, rivaroxaban, warfarin



  1. Cole, Connie S. DNP, RN-BC, NP-C
  2. Zimmerman, Richard MS, RN, CCRN, FNP-BC


Abstract: Direct oral anticoagulants (DOACs) have expanded options for treating patients with atrial fibrillation (AF). However, DOACs are not warfarin substitutes, and NPs need to be aware of the difference. DOACs are first-line agents when treating AF, yet warfarin has not been replaced. Individualized patient characteristics drive current guidelines.